CA2915250A1 - Cell stabilization - Google Patents

Cell stabilization Download PDF

Info

Publication number
CA2915250A1
CA2915250A1 CA2915250A CA2915250A CA2915250A1 CA 2915250 A1 CA2915250 A1 CA 2915250A1 CA 2915250 A CA2915250 A CA 2915250A CA 2915250 A CA2915250 A CA 2915250A CA 2915250 A1 CA2915250 A1 CA 2915250A1
Authority
CA
Canada
Prior art keywords
inhibitor
composition
cell
formulation
apoptosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2915250A
Other languages
English (en)
French (fr)
Inventor
Judy Muller-Cohn
Paul Diaz
Rolf Muller
Vasco LIBERAL
Albert PEREZ-LADAGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomatrica Inc
Original Assignee
Biomatrica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomatrica Inc filed Critical Biomatrica Inc
Publication of CA2915250A1 publication Critical patent/CA2915250A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2915250A 2013-06-13 2014-06-13 Cell stabilization Abandoned CA2915250A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361834517P 2013-06-13 2013-06-13
US61/834,517 2013-06-13
PCT/US2014/042396 WO2015002729A2 (en) 2013-06-13 2014-06-13 Cell stabilization

Publications (1)

Publication Number Publication Date
CA2915250A1 true CA2915250A1 (en) 2015-01-08

Family

ID=52144261

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2915250A Abandoned CA2915250A1 (en) 2013-06-13 2014-06-13 Cell stabilization

Country Status (6)

Country Link
US (2) US20160135446A1 (enExample)
EP (2) EP3007556B1 (enExample)
JP (1) JP6604942B2 (enExample)
CN (1) CN105491883B (enExample)
CA (1) CA2915250A1 (enExample)
WO (1) WO2015002729A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687580A (zh) * 2014-06-10 2017-05-17 生物马特里卡公司 在环境温度下稳定血液样品中的代谢活性细胞

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9725703B2 (en) 2012-12-20 2017-08-08 Biomatrica, Inc. Formulations and methods for stabilizing PCR reagents
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015191632A1 (en) 2014-06-10 2015-12-17 Biomatrica, Inc. Stabilization of thrombocytes at ambient temperatures
HK1258397A1 (zh) 2015-09-09 2019-11-08 Drawbridge Health, Inc. 用於样品收集、稳定化和保存的系统、方法和装置
ES2946184T3 (es) 2015-12-08 2023-07-13 Biomatrica Inc Reducción de la velocidad de eritrosedimentación
JPWO2017130756A1 (ja) * 2016-01-25 2018-11-29 学校法人慶應義塾 小胞体ストレスを標的とする椎間板変性症に対する治療薬
KR101662975B1 (ko) * 2016-02-15 2016-10-06 서울대학교산학협력단 간암 치료 또는 예방용 조성물
KR102451535B1 (ko) 2016-03-31 2022-10-05 버클리 라잇츠, 인크. 핵산 안정화 시약, 키트들, 및 그 이용 방법들
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
WO2018138358A1 (en) 2017-01-30 2018-08-02 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
CN106963769B (zh) * 2017-03-03 2019-10-25 深圳大学 含pi3k抑制剂和perk抑制剂的药物组合物及其应用
GB201804227D0 (en) * 2018-03-16 2018-05-02 Univ Warwick Cryopreserving compositions
CN114615886A (zh) * 2019-08-29 2022-06-10 得克萨斯大学体系董事会 细胞冷冻保存培养基
CN111418579B (zh) * 2020-04-13 2021-05-18 广东华夏健康生命科学有限公司 一种脂肪组织的保存方法、脂肪组织的保存液及其制备方法
CN116322696A (zh) 2020-05-04 2023-06-23 安进公司 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
CN112210593B (zh) * 2020-11-12 2023-09-19 苏州创澜生物科技有限公司 一种冻干保护剂、可冻干的pcr试剂及其应用
CN112210594B (zh) * 2020-11-12 2023-09-19 苏州创澜生物科技有限公司 一种逆转录试剂的冻干保护剂
CN113261557A (zh) * 2021-05-28 2021-08-17 广东先康达生物科技有限公司 一种干细胞冻存液及干细胞冻存方法
CN115363016B (zh) * 2022-08-09 2023-07-18 广州明迅生物科技有限责任公司 细胞储存液及其应用
CN115777693B (zh) * 2023-02-03 2023-04-18 苏州依科赛生物科技股份有限公司 一种细胞冻存液、制备方法、应用方法及用途
WO2025240630A1 (en) * 2024-05-14 2025-11-20 Abbott Laboratories Reagent compositions for isothermal amplification of nucleic acids

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US918A (en) 1838-09-14 Improvement in the mode of regulating windmills
US7037A (en) 1850-01-22 Grid-ikon slide-valve
JPH0244514B2 (ja) * 1981-09-14 1990-10-04 Nippon Oil Co Ltd Biseibutsuseikintainokoteika*zoshokuho
WO1992011864A1 (en) * 1991-01-11 1992-07-23 Cryopharm Corporation Method of detecting circulating antibody types using dried or lyophilized cells or cell-like material
US5242792A (en) * 1991-02-25 1993-09-07 The United States Of America As Represented By The Secretary Of The Navy Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides
US5541290A (en) 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
JP4421681B2 (ja) * 1995-10-19 2010-02-24 バイオ‐オリジン エルエルシー 生殖細胞および胚の生存および機能を改善する方法および組成物
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6821963B2 (en) 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US7064193B1 (en) * 1997-09-17 2006-06-20 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7001770B1 (en) 1998-10-15 2006-02-21 Canji, Inc. Calpain inhibitors and their applications
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
IL149778A0 (en) * 1999-11-22 2002-11-10 Universal Preservation Technologies Inc Preservation of sensitive biological material
CN1272328C (zh) 1999-12-17 2006-08-30 希龙公司 糖元合成酶激酶3的基于吡嗪的抑制剂
ES2246927T3 (es) 1999-12-17 2006-03-01 Chiron Corporation Inhibidores biciclicos de glucogeno sintasa quinasa 3.
JP3694730B2 (ja) * 2000-03-02 2005-09-14 国立大学法人京都大学 組織の冷却保存液
US7001905B2 (en) 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
US6608632B2 (en) 2000-06-12 2003-08-19 Sharp Laboratories Of America, Inc. Methods and systems for improving display resolution in images using sub-pixel sampling and visual error filtering
DE60140707D1 (de) 2000-07-27 2010-01-14 Novartis Vaccines & Diagnostic GSK3-Polypeptide
US6872357B1 (en) * 2000-11-22 2005-03-29 Quadrant Drug Delivery Limited Formulation of preservation mixtures containing sensitive biologicals to be stabilized for ambient temperature storage by drying
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US20040110267A1 (en) * 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
MXPA03008888A (es) 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
JP2006512102A (ja) * 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
GB0218800D0 (en) 2002-08-13 2002-09-18 Celltech R&D Ltd Chemical compounds
GB0228832D0 (en) * 2002-12-10 2003-01-15 Novartis Ag Organic compound
AU2004249495A1 (en) 2003-06-20 2004-12-29 Ucb Pharma S.A. Thienopyridone derivatives as kinase inhibitors
GB0314607D0 (en) * 2003-06-23 2003-07-30 Univ Cambridge Tech Preservation method
AU2004203373A1 (en) 2003-07-25 2005-02-10 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
US7314755B2 (en) * 2003-10-15 2008-01-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Preservation of eukaryotic cells using reversible pore formation
WO2005042540A1 (en) 2003-10-24 2005-05-12 Celltech R & D Limited Thieno-pyridinone derivatives as kinase inhibitors
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
ES2243131B1 (es) 2004-05-07 2007-02-01 Consejo Sup. Investig. Cientificas Tiamidas derivadas de bifenilo como inhibidores de calpaina.
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
ES2255848B1 (es) 2004-12-16 2007-07-01 Consejo Superior Investig. Cientificas Derivados de isoquinolina como inhibidores de calpaina.
AP2007004244A0 (en) 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
AU2006279700A1 (en) * 2005-08-11 2007-02-22 President And Fellows Of Harvard College Methods and compositions for dried cellular forms
WO2008048228A2 (en) * 2005-08-12 2008-04-24 Department Of The Army Glycine stabilized lyophilized plasma
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2007101225A2 (en) 2006-02-27 2007-09-07 The Board Of Trustees Of The Leland Stanford Junior University Methods to identify inhibitors of the unfolded protein response
AU2007237901B2 (en) 2006-04-18 2012-07-05 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors
WO2008007463A1 (fr) * 2006-07-12 2008-01-17 Nippon Zenyaku Kogyo Co., Ltd. Composition de dilution et de stockage de sperme
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
WO2010008843A1 (en) 2008-06-24 2010-01-21 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
JP5615274B2 (ja) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Ｍｅｋキナーゼインヒビターとしてのイソインドロン誘導体及びその使用方法
WO2010046949A1 (ja) * 2008-10-22 2010-04-29 Inui Hiroaki 細胞をガラス化保存する方法および細胞のガラス化保存用容器
AU2009307161A1 (en) * 2008-10-22 2010-04-29 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Preservation mixture and use thereof
CA2761675A1 (en) 2009-05-11 2010-11-18 Biomatrica, Inc. Compositions and methods for biological sample storage
SG176253A1 (en) * 2009-05-26 2011-12-29 Advanced Bionutrition Corp Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2555918A1 (en) * 2010-04-06 2013-02-13 Genvault Corporation Stabilized chemical dehydration of biological material
US8440665B2 (en) 2010-07-02 2013-05-14 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
US9376709B2 (en) * 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en) * 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US20120028933A1 (en) * 2010-07-28 2012-02-02 Baust John M Cell Culture Media Supplement and Method of Molecular Stress Control
US8664244B2 (en) 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
WO2012067240A1 (ja) * 2010-11-19 2012-05-24 セーレン株式会社 細胞のガラス化保存液

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687580A (zh) * 2014-06-10 2017-05-17 生物马特里卡公司 在环境温度下稳定血液样品中的代谢活性细胞

Also Published As

Publication number Publication date
EP3007556B1 (en) 2020-05-20
EP3007556A4 (en) 2017-03-08
EP3632208A1 (en) 2020-04-08
CN105491883B (zh) 2018-11-02
US20180184644A1 (en) 2018-07-05
JP2016522221A (ja) 2016-07-28
WO2015002729A3 (en) 2015-05-07
US20160135446A1 (en) 2016-05-19
CN105491883A (zh) 2016-04-13
WO2015002729A2 (en) 2015-01-08
EP3007556A2 (en) 2016-04-20
JP6604942B2 (ja) 2019-11-13

Similar Documents

Publication Publication Date Title
EP3007556B1 (en) Cell stabilization
Hyeon et al. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation
Mullany et al. Distinct proliferative and transcriptional effects of the D-type cyclins in vivo
Ruan et al. Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury
Yamamoto et al. Fertilization-induced autophagy in mouse embryos is independent of mTORC1
CN111655258B (zh) 用于冷冻保存的组合物和其使用方法
Izuishi et al. Ischemic preconditioning of the murine liver protects through the Akt kinase pathway
WO2015184375A2 (en) Compositions and methods for promoting intestinal stem cell and/or non-stem progenitor cell function
Hu et al. Hypoxic preconditioning increases survival of cardiac progenitor cells via the pim-1 kinase-mediated anti-apoptotic effect
Hakim et al. FAK regulates cardiomyocyte survival following ischemia/reperfusion
Wang et al. Downregulation of the zinc transporter SLC39A13 (ZIP13) is responsible for the activation of CaMKII at reperfusion and leads to myocardial ischemia/reperfusion injury in mouse hearts
Manoharan et al. Thioredoxin inhibits MPK38-induced ASK1, TGF‐β, and p53 function in a phosphorylation-dependent manner
Yang et al. Hypothermic machine perfusion increases A20 expression which protects renal cells against ischemia/reperfusion injury by suppressing inflammation, apoptosis and necroptosis
JP2013536208A5 (enExample)
TW202106870A (zh) 包含海藻醣之哺乳動物細胞保存用液
Choi et al. Regulation of ROS-independent ERK signaling rescues replicative cellular senescence in ex vivo expanded human c-kit-positive cardiac progenitor cells
Jian et al. Pivotal role of activating transcription factor 6α in myocardial adaptation to chronic hypoxia
JP2020529204A (ja) 保存中の精子の品質及び機能を向上させるｍＴＯＲの強化及び使用
KR20200119570A (ko) 누에의 저장 단백질 1을 유효성분으로 포함하는 자가포식 억제용 조성물 및 자가포식 매개 질환의 약학적 조성물
TW202444394A (zh) 用於懸浮細胞之液體及其利用
Al-Otaibi Cryomedia Formula: Cellular Molecular Perspective
Alfar Cardiac molecular defects in an in vitro disease model of Vici syndrome and identification of potential therapeutic target
藤田泰毅 et al. Study on preservation solutions for therapy with human adipose tissue-derived mesenchymal stromal cells
Damri et al. MGR2 Depletion Affects Protein Import and Mitochondrial Metabolism
Huang The regulation of protein synthesis in adult rat cardiomyocytes

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831